Tesamorelin
Tesamorelin (Egrifta): the one approved use, what trials showed, side effects and how the vial is reconstituted.
FDA-approved, narrow use · Evidence grade B · Reviewed
Tesamorelin (Egrifta). Growth-hormone-releasing hormone analog.
BFDA-approved, narrow use. Evidence grade B: human trials, narrow or pending approval.
What is Tesamorelin?
Tesamorelin prompts the pituitary gland to release growth hormone.
Is Tesamorelin FDA-approved?
Approved in November 2010 for one purpose: reducing excess abdominal fat in people with HIV who have lipodystrophy. It is not approved for general weight loss, and it is not eligible for pharmacy compounding because FDA treats it as a biological product.
What does the evidence show for Tesamorelin?
Two placebo-controlled trials in 816 adults with HIV showed greater reductions in abdominal fat. Evidence outside that group is limited.
What are the known risks of Tesamorelin?
Joint pain, injection-site reactions, stomach pain, swelling and muscle pain were the most common. Blood sugar control worsened more often than with placebo.
How is Tesamorelin measured?
Supplied as a powder vial that is reconstituted before use. Follow the product instructions. The Mix mode shows the arithmetic.
Sources: News-Medical: Egrifta FDA approval; Portrait: sermorelin and tesamorelin FDA records. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.